Immunocore Holdings PLC reports results for the quarter ended in December - Earnings Summary
28/02/2024 16:58
* Immunocore Holdings PLC IMCR.OQ reported a quarterly
adjusted
loss of 32 pence per share for the quarter ended in December,
higher than the same quarter last year, when the company
reported EPS of -54 pence. The mean expectation of
seventeen analysts for the quarter was for a loss of 22 pence
per share. Wall Street expected results to range from -44 pence
to -5 pence per share.
* Revenue rose 17.6% to £56.52 million from a year ago;
analysts
expected £53.33 million.
* Immunocore Holdings PLC's reported EPS for the quarter was
a
loss of 32 pence.
* The company reported a quarterly loss of £15.9 million.
* Immunocore Holdings PLC shares had risen by 3.1% this
quarter.
FORECAST CHANGES
* The mean earnings estimate of analysts had fallen by
about 2.3%
in the last three months.
* In the last 30 days, there have been no negative revisions
of
earnings estimates
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 16 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"
Wall Street's median 12-month price target for Immunocore
Holdings PLC is $84.00
This summary was machine generated from LSEG data February 28 at
04:57 p.m. UTC. All figures in pounds unless otherwise stated.
(For questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Dec. 31 2023 -0.22 -0.32 Missed
Sep. 30 2023 -0.29 0.04 Beat
Jun. 30 2023 -0.32 -0.29 Beat
Mar. 31 2023 -0.32 -0.35 Missed